In conclusion, we demonstrate that CuD overcomes gefitinib resistance by reducing the activation of EGFR-mediated survival in NSCLC and by inhibiting the combination of EGF and EGFR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.